NVO News and Press, Novo Nordisk A/S From 07/13/24

2024-07-13 14:03:47 ET More on Amgen, Biogen, etc. Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024 Merck: Positive Developments, But Watch The Q2 Earnings Biogen Stock: Cheapish, But With Few Growth Prospects This weight loss stock is the...

2024-07-12 10:50:24 ET Read the full article on Seeking Alpha For further details see: These are the weight loss drug stocks with the most upside - SA Sentiment Survey

2024-07-12 10:27:31 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk once-weekly insulin rejected by FDA ...

2024-07-12 04:12:28 ET More on Amgen Amgen: Biotech Leader Riding High On Obesity Drug Euphoria (Downgrade) Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum Amgen: You Haven't Seen Anything Yet Lilly, Novo Nordisk to dominate weight lo...

2024-07-11 14:19:51 ET Summary Pfizer Inc. announced today that it planned to continue development of its GLP-1 agonist weight loss drug danuglipron as a once-daily oral pill. The drug met efficacy endpoints in a Phase 2 study last year as a twice daily pill, but side effects caus...

2024-07-11 13:19:08 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Most patients discontinue Novo’s Wegovy, Ozempic ...

2024-07-11 07:18:20 ET Buoyed by encouraging pharmacokinetic data from an ongoing study, Pfizer ( NYSE: PFE ) has decided to proceed with the development of a once-daily formulation of its oral weight-loss drug, danuglipron.... Read the full article on Seeking Alpha ...

2024-07-10 08:25:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Strategy lagged sl...

2024-07-10 08:19:40 ET More on Novo Nordisk Novo Nordisk: Buy On Dips Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy Novo Nordisk: Leading The Fight Against Diabetes And Obesity Study finds patients lost more weight on Mounjaro than O...

2024-07-09 22:22:11 ET Summary VIGI has underperformed due to market-wide preference for US mega-cap stocks, but valuation and diversification may lead to mean reversion favoring VIGI. 2Q is expected to mark the first growth quarter for "Other" 493, a potential catalyst for change...